<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505255</url>
  </required_header>
  <id_info>
    <org_study_id>GIT motility after lap.</org_study_id>
    <nct_id>NCT03505255</nct_id>
  </id_info>
  <brief_title>Comparison Between Intraperitoneal Versus Intramuscular Neostigmine on Pattern of Postoperative GIT Motility in Patients Undergoing Laparoscopic Cholecystectomy</brief_title>
  <official_title>Comparison Between Intraperitoneal Versus Intramuscular Neostigmine on Pattern of Postoperative GIT Motility in Patients Undergoing Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal in this work is to compare between the effects of intraperitoneal versus
      intramuscular neostigmine on pattern of postoperative GIT motility in patients undergoing
      laparoscopic cholecystectomy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite numerous advances in surgical technique and perioperative care, postoperative ileus
      (POI) continues to be one of the most common and expected aspects of abdominal surgery. It
      prolongs hospital stays, increases medical costs and frustrates patients and surgeons.

      Many authors suggest that POI is a mandatory phase of the recovery period for any
      intra-abdominal procedure, and only an ileus lasting greater than 5 days is abnormal - to be
      termed a prolonged POI.

      Under this definition, fully 40% of patients undergoing laparotomy experience prolonged
      postoperative ileus.

      In 2006, different types of postoperative ileus (primary, secondary, recurrent, prolonged)
      were defined through consensus, and prolonged postoperative ileus was defined as absence of
      bowel function after the third postoperative day for laparoscopic surgery and after the fifth
      postoperative day for open abdominal surgery.

      What constitutes prolonged postoperative ileus is debated, with many different definitions
      reported; consequently reported incidences range from 3% to 32%. Neostigmine is a
      cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the
      neuromuscular junction, thereby increasing contractions in the normal gut.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>passing flatus</measure>
    <time_frame>each 2 hours</time_frame>
    <description>A questionnaire for each patient about the first time to pass flatus or stool</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barium meal</measure>
    <time_frame>after 4 hours, 24hours, 48 hours</time_frame>
    <description>Upon regaining consciousness in the recovery room after operation, the patient will be asked to swallow another 30 cc. of liquid barium and 4 hours later abdominal roentgenogram film will be taken.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Pattern of GIT Motility</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: 40 patients will receive intraperitoneal neostigmine 0.25 mg in 30 ml normal saline and 1 ml normal saline intramuscular.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B: 40 patients will receive intraperitoneal neostigmine 0.5 mg in 30 ml normal saline and 1 ml normal saline intramuscular.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C: 40 patients will receive intramuscular neostigmine 0.5 mg in 1 ml volume plus 30 ml normal saline intraperitoneal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group D (control group): 40 patients will receive intraperitoneal 30 ml normal saline and 1 ml normal saline intramuscular.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neostigmine</intervention_name>
    <description>Neostigmine is a cholinesterase-inhibitor, which augments the concentration of acetylcholine (ACh) at the neuromuscular junction</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline 0.9 % is given in the control group</description>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ASA status I and II patients, aged between 20 and 60 years, who are scheduled for
        laparoscopic cholecystectomy.

        Exclusion Criteria:

        Patients with electrolyte imbalance Patients with diabetes mellitus Patients who are addict
        to opioids Patients with neurological defects or paralysis or preoperative recumbence.
        Patients with atrial-ventricular conduction disturbances, sinus bradycardia &lt; 60 BPM or a
        nodal rhythm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haitham Mohammad Ahmad Mohammad, Assistant lecturer</last_name>
    <phone>01067330721</phone>
    <email>hythemmoh@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayman Ahmed Mamdouh, Associate Professor</last_name>
    <phone>01066066001</phone>
    <email>aymanosman2000@yahoo.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Baig MK, Wexner SD. Postoperative ileus: a review. Dis Colon Rectum. 2004 Apr;47(4):516-26. Epub 2004 Feb 25. Review. Retraction in: Wexner SD. Dis Colon Rectum. 2005 Oct;48(10):1983. Dis Colon Rectum. 2005 Oct;48(10):1983.</citation>
    <PMID>14978625</PMID>
  </reference>
  <reference>
    <citation>Delaney CP, Wolff BG, Viscusi ER, Senagore AJ, Fort JG, Du W, Techner L, Wallin B. Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg. 2007 Mar;245(3):355-63.</citation>
    <PMID>17435541</PMID>
  </reference>
  <reference>
    <citation>Schuster R, Grewal N, Greaney GC, Waxman K. Gum chewing reduces ileus after elective open sigmoid colectomy. Arch Surg. 2006 Feb;141(2):174-6.</citation>
    <PMID>16490895</PMID>
  </reference>
  <reference>
    <citation>Sajja SB, Schein M. Early postoperative small bowel obstruction. Br J Surg. 2004 Jun;91(6):683-91. Review.</citation>
    <PMID>15164435</PMID>
  </reference>
  <reference>
    <citation>Viscusi ER, Goldstein S, Witkowski T, Andonakakis A, Jan R, Gabriel K, Du W, Techner L, Wallin B. Alvimopan, a peripherally acting mu-opioid receptor antagonist, compared with placebo in postoperative ileus after major abdominal surgery: results of a randomized, double-blind, controlled study. Surg Endosc. 2006 Jan;20(1):64-70. Epub 2005 Dec 7. Erratum in: Surg Endosc. 2006 Mar;20(3):537.</citation>
    <PMID>16333556</PMID>
  </reference>
  <reference>
    <citation>Husebye E. Gastrointestinal motility disorders and bacterial overgrowth. J Intern Med. 1995 Apr;237(4):419-27. Review.</citation>
    <PMID>7714466</PMID>
  </reference>
  <reference>
    <citation>Holte K, Kehlet H. Postoperative ileus: a preventable event. Br J Surg. 2000 Nov;87(11):1480-93. Review.</citation>
    <PMID>11091234</PMID>
  </reference>
  <reference>
    <citation>Goyal RK, Hirano I. The enteric nervous system. N Engl J Med. 1996 Apr 25;334(17):1106-15. Review. Erratum in: N Engl J Med 1996 Jul 18;335(3):215.</citation>
    <PMID>8598871</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Haitham Mohammad Ahmad Mohammad</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neostigmine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

